Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.7379 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4722 | 0.4688 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.4439 | 0.4403 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.0603 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.7379 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.8876 | 0.5 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.7379 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.0004 | 0.0082 | 0.1363 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0004 | 0.0082 | 0.1363 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4722 | 0.4688 |
Trypanosoma brucei | ISWI complex protein | 0.0004 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Trypanosoma cruzi | ISWI complex protein | 0.0004 | 0 | 0.5 |
Plasmodium falciparum | zinc finger protein, putative | 0.0004 | 0.0064 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.7379 | 1 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0004 | 0.0082 | 0.1363 |
Onchocerca volvulus | 0.0035 | 0.4439 | 0.5 | |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.7379 | 0.7362 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.4722 | 0.6015 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.1014 | 0.0453 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.4722 | 0.6015 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.7379 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.7379 | 0.7362 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.7379 | 0.7362 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.4439 | 0.5381 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.7379 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0005 | 0.0191 | 0.0127 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0603 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0711 | 0.0651 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.1014 | 0.0453 |
Entamoeba histolytica | hypothetical protein | 0.0004 | 0.0064 | 0.5 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.4439 | 0.5396 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0603 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 50 um | PUBCHEM_BIOASSAY: 14-3-3 protein interaction modulators Dose Response Confirmation. (Class of assay: confirmatory) [Related pubchem assays: 422 (Primary screen preceding this dose response confirmation assay.)] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.